Clinical Trial Update: Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating lubiprostone as a modulator of gut microbial translocation in HIV patients with incomplete CD4 recovery on ART.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• LUBIPROSTONE (lubiprostone)

Snippet

Sponsor: Ruth M. Rothstein CORE Center | Conditions: HIV | Phase 2 | Status: COMPLETED | Results posted: 2023-08-30